甲磺酸伊马替尼治疗复发或转移胃肠间质瘤35例  

Treatment of recurrent or metastatic gastrointestinal stromal tumors with imatinib mesylate of 35 cases report

作　　者：高伟[1] 薛春燕[1] 王雅杰[1] 

机构地区：[1]第二军医大学附属长海医院肿瘤科,上海200433

出　　处：《中国综合临床》2012年第5期517-519,共3页Clinical Medicine of China

摘　　要：目的探讨甲磺酸伊马替尼治疗复发或转移胃肠间质瘤的疗效。方法对我院2007年1月至2010年2月收治的35例经甲磺酸伊马替尼治疗的复发或转移胃肠间质瘤患者的临床资料进行回顾性分析。结果服药3个月：完全缓解1例（2．9％，1／35），部分缓解16例（45．7％，16／35），稳定18例（51．4％，18／35），进展0例，临床获益率100％（35／35）。2年生存率97．1％，2年无进展生存率82．9％。结论甲磺酸伊马替尼治疗复发或转移胃肠间质瘤具有较好的治疗效果且安全可靠。Objective To investigate the effects of imatinib mesylate on recurrent or metastatic gastrointestinal stromal tumor. Methods Thirty-five cases of patients with recurrent or metastatic gastrointestinal stromal tumors treated with Imatinib mesylate from January 2007 to February 2010 in our hospital were analyzed retrospectively. Results After treated with Imatinib mesylate for 3 months, complete remission rate was 2. 9% （ 1/35 ）, partial remission rate was 45.7% （ 16/35 ）, stable disease rate was 5l. 4% （ 18/35 ）and progressive rate was 0;clinical benefit rate was 100%. The 2-year overall survival rate was 97. 1%. The 2-year progression free survival was 82. 9%. Conclusion Imatinib mesylate is effective for recurrent or metastatic gastrointestinal stromal tumors and the treatment is safe and reliable.

关 键 词：胃肠间质瘤 甲磺酸伊马替尼 复发 转移 

分 类 号：R735[医药卫生—肿瘤]